Literature DB >> 21474497

Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD.

Catherina L Chang1, Scott C Robinson, Graham D Mills, Glenda D Sullivan, Noel C Karalus, John D McLachlan, Robert J Hancox.   

Abstract

BACKGROUND: Retrospective studies suggest that plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin T are often elevated in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) and are associated with increased mortality. These cardiac biomarkers were investigated in an unselected cohort of patients admitted to hospital with exacerbations of COPD.
METHODS: Consecutive patients with physician-diagnosed COPD exacerbation but without clinical evidence of acute cardiac disease admitted to a public hospital over a 1 year period were studied prospectively. NT-proBNP and troponin T were measured on admission. The primary end point was all-cause mortality at 30 days.
RESULTS: Elevated NT-proBNP (>220 pmol/l) was present in 65/244 patients (27.5%) and significantly predicted 30-day mortality (OR 9.0, 95% CI 3.1 to 26.2, p<0.001). Elevated troponin T (>0.03 μg/l) was found in 40/241 patients (16.6%) and also predicted 30-day mortality (OR 6.3, 95% CI 2.4 to 16.5, p<0.001). These associations persisted after adjusting for other clinical and laboratory predictors of mortality (arterial CO(2) pressure (Paco(2)), body mass index and CURB65 score). NT-proBNP and troponin T levels appeared to have additive associations with mortality: 30-day mortality among patients with abnormalities of both NT-proBNP and troponin T was 15-fold higher than among patients with normal values.
CONCLUSION: Elevated levels of NT-proBNP and troponin T are strong predictors of early mortality among patients admitted to hospital with acute exacerbations of COPD independently of other known prognostic indicators. The pathophysiological basis for this is unknown, but indicates that cardiac involvement in exacerbations of COPD may be an important determinant of prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21474497     DOI: 10.1136/thx.2010.155333

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  64 in total

1.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han
Journal:  Respir Med       Date:  2018-06-05       Impact factor: 3.415

2.  N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).

Authors:  Ilija Andrijevic; Senka Milutinov; Zagorka Lozanov Crvenkovic; Jovan Matijasevic; Ana Andrijevic; Tomi Kovacevic; Darijo Bokan; Bojan Zaric
Journal:  Lung       Date:  2018-06-27       Impact factor: 2.584

3.  Evaluation of platelet lymphocyte ratio and 90-day mortality in patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Praneel Kumar; Stephanie Law; Krishna B Sriram
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

4.  Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors.

Authors:  Jennifer Y So; Huaqing Zhao; Helen Voelker; Robert M Reed; Donald Sin; Nathaniel Marchetti; Gerard J Criner
Journal:  Ann Am Thorac Soc       Date:  2018-11

5.  Impact of Left Ventricular Hypertrophy on Survival in Chronic Obstructive Pulmonary Disease.

Authors:  Philip M Short; William J Anderson; Douglas H J Elder; Allan D Struthers; Brian J Lipworth
Journal:  Lung       Date:  2015-03-29       Impact factor: 2.584

Review 6.  Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

Authors:  Alvar Agustí; Peter M Calverley; Marc Decramer; Robert A Stockley; Jadwiga A Wedzicha
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

Review 7.  Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations.

Authors:  Kenan Yalta; Tulin Yalta; Muhammet Gurdogan; Orkide Palabıyık; Ertan Yetkın
Journal:  Curr Allergy Asthma Rep       Date:  2020-04-28       Impact factor: 4.806

8.  β-Blockers are associated with a reduction in COPD exacerbations.

Authors:  Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield
Journal:  Thorax       Date:  2015-08-17       Impact factor: 9.139

Review 9.  Personalised medicine and asthma diagnostics/management.

Authors:  Samuel J Wadsworth; Andrew J Sandford
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

10.  β-Adrenoceptor blockers and pulmonary function in the general population: the Rotterdam Study.

Authors:  Daan W Loth; Guy G Brusselle; Lies Lahousse; Albert Hofman; Hubert G M Leufkens; Bruno H Stricker
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.